GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Antimicrobial peptides (AMPs), also called host defence peptides (HDPs) are part of the innate immune response found among all classes of life. Fundamental differences exist between prokaryotic and eukaryotic cells that may represent targets for antimicrobial peptides. These peptides are potent, broad spectrum antimicrobials which demonstrate potential as novel therapeutic agents. Antimicrobial peptides have been demonstrated to kill Gram negative and Gram positive bacteria, enveloped viruses, fungi and even transformed or cancerous cells. Unlike the majority of conventional antibiotics it appears that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to enhance immunity by functioning as immunomodulators.
In 2015, the first ionization energy of lawrencium was measured, using the isotope 256Lr. The measured value, 4.96+0.08−0.07 eV, agreed very well with the relativistic theoretical prediction of 4.963(15) eV, and also provided a first step into measuring the first ionization energies of the transactinides. This value is the lowest among all the lanthanides and actinides, and supports the s2p configuration as the 7p1/2 electron is expected to be only weakly bound. As ionisation energies generally increase left to right in the f-block, this low value suggests that lutetium and lawrencium belong in the d-block (whose trend they follow) and not the f-block. That would make them the heavier congeners of scandium and yttrium, rather than lanthanum and actinium. Although some alkali metal-like behaviour has been predicted, adsorption experiments suggest that lawrencium is trivalent like scandium and yttrium, not monovalent like the alkali metals. A lower limit on lawrencium's second ionization energy (>13.3 eV) was experimentally found in 2021. Even though s2p is known to be the ground-state configuration of the lawrencium atom, ds2 should be a low-lying excited-state configuration, with an excitation energy variously calculated as 0.156 eV, 0.165 eV, or 0.626 eV. As such lawrencium may still be considered to be a d-block element, albeit with an anomalous electron configuration (like chromium or copper), as its chemical behaviour matches expectations for a heavier analogue of lutetium.
Sulfonylureas or sulphonylureas are a class of organic compounds used in medicine and agriculture. The functional group consists of a sulfonyl group (-S(=O)2) with its sulphur atom bonded to a nitrogen atom of a ureylene group (N,N-dehydrourea, a dehydrogenated derivative of urea). The side chains R1 and R2 distinguish various sulfonylureas. In humans, sulfonylureas are medically used in the management of type 2 diabetes by stimulating insulin secretion. Sulfonylureas are the most widely used herbicide.
Sources: en.wikipedia.org
== Distinctions and honors == During his life, Jones was awarded 61 patents. Forty were for refrigeration equipment, while others were for devices for theater equipment and devices pertaining to gasoline engines.
==== Philippines ==== In the Philippines, the sweet delicacy tahô is made of fresh tofu (vendors scooped from a wooden bucket with a flat spoon) with brown palm or pandan-flavored sugar syrup and sagó.
== Deaths == 2 March - Robert Watkin Wynne, politician, 52? 12 April - Evan Davies, Independent minister, 56 19 September - John Roberts, hymn-writer, 75 October - Gabriel Jones, Welsh American lawyer and politician, 82 4 October - Samuel Horsley, Bishop of St Asaph date unknown Fulke Greville, former MP for Monmouth Boroughs
Sources: en.wikipedia.org
One prominent case was the classification of ascolichen families by the structure of the ascus apex (the tip of the spore sac). Josef Hafellner (1984) reorganized many ascolichen families by ascus-apex staining (amyloid ring present vs. absent), treating that feature as primary. Later DNA work found several of those families to be polyphyletic: the ascus type had arisen independently in unrelated lineages. The results echoed Nylander's century-old warning against single-trait taxonomy. Leif Tibell (1998) urged that robust taxa rest on multiple, independent characters. Pier Luigi Nimis (1998) warned that elevating every apparent clade to genus rank risks "explosive inflation" and listed five tests—monophyly, formal analysis, ≥ 1 diagnostic trait, broad sampling, and demonstrable informational gain—before renaming species. Where those tests are not met, Nimis advised using subgeneric rank so that binomials remain stable. Tibell further separated goals: classification should provide a stable, useful scheme, whereas phylogeny seeks the full branching pattern. He argued that constant renaming for every new tree can undermine nomenclatural stability; revisions should await strong, multi-line evidence. These philosophical perspectives influenced how lichenologists handled emerging molecular results a few years later. By the late 1990s lichenologists, trained in data matrices and synapomorphy logic, were ready to fold DNA data into taxonomy.
PI3K can also be activated by G protein-coupled receptors (GPCR), via G-protein βγ dimers or Ras which bind PI3K directly. In addition, the Gα subunit activates Src-dependent integrin signaling which can activate PI3K. Activated PI3K catalyses the addition of phosphate groups to the 3'-OH position the inositol ring of phosphoinositides (PtdIns), producing three lipid products, PI(3)P, PI(3,4)P2 and PI(3,4,5)P3: Phosphatidylinositol (PI) → PI 3-phosphate, (PI(4)P) → PI 3,4-bisphosphate, (PI(4,5)P2) → PI 3,4,5-triphosphate These phosphorylated lipids are anchored to the plasma membrane, where they can directly bind intracellular proteins containing a pleckstrin homology (PH) or FYVE domain. For example, the triphosphate form (PI(3,4,5)P3) binds Akt and phosphoinositide-dependent kinase 1 (PDK1) so they accumulate in close proximity at the membrane.
Uranium-232 has a half-life of 68.9 years and is a side product in the thorium cycle. It has been cited as an obstacle to nuclear proliferation using 233U, because the intense gamma radiation from 208Tl (a daughter of 232U, produced relatively quickly) makes 233U contaminated with it more difficult to handle. Uranium-232 is a rare example of an even-even isotope that is fissile with both thermal and fast neutrons.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.